RxDoctor Payments Data

Khaled Chan, MD

Internal Medicine · Westminster, CANPI 1255376414

Payments from drug & device makers

$4,919in general payments, 2019–2025

Across 41 payments — averaging $119.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$4K
  • GSK$278
  • Avadel CNS Pharmaceuticals, LLC$118
  • Viatris Specialty LLC$96
  • AstraZeneca$76
  • Amgen$45
  • plus $306 from 12 others

What the payments were for

  • Food & beverage$919100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,919 in reported general payments places this provider in the 85th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$1,064,495
Medicare patients
724
Services billed
9,282

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TracleerBosentan13$153,107
Dupixent PenDupilumab38$140,597
Spiriva RespimatTiotropium Bromide94$51,626
XifaxanRifaximin19$29,062
EliquisApixaban46$28,244
Breztri AerosphereBudesonide/Glycopyr/Formoterol34$26,517
Trelegy ElliptaFluticasone/Umeclidin/Vilanter27$21,927
Advair HfaFluticasone Propion/Salmeterol33$14,748
Qvar RedihalerBeclomethasone Dipropionate33$11,546
JanuviaSitagliptin Phosphate33$9,378
Incruse ElliptaUmeclidinium Bromide22$8,101
DuleraMometasone/Formoterol24$7,916
Combivent RespimatIpratropium/Albuterol Sulfate12$6,291
Fluticasone Propionate HfaFluticasone Propionate21$6,144
SymbicortBudesonide/Formoterol Fumarate17$5,500

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimSpiriva Respimat, Combivent Respimat$4,000$57,917106 claims
AstraZenecaBreztri Aerosphere, Symbicort, Pulmicort Flexhaler$76$34,62264 claims
GSKTrelegy Ellipta, Incruse Ellipta$278$30,02849 claims
Lilly USA, LLCOlanzapine$34$62820 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Westminster

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →